Formulation and evaluation of trimetazidine hydrochloride transdermal patches

Abstract

Angina is usually caused by an underlying obstruction to the coronary artery due to atherosclerosis. The most

common symptom is chest pain that occurs behind the breastbone or slightly to the left of it. The pain of stable

angina usually begins slowly. The current aim focuses on to fabricate Trimetazidine Hydrochloride monolithic

transdermal films using various polymers like chitosan, Hydroxypropylmethylcellulose, Polyvinyl alcohol,

Methyl cellulose and Ethyl cellulose. The results shows that the marketed tablet released 96.41% of drug in 40

minutes and whereas the formulation F3 released 92.10% in 24 hrs. Thus prepared transdermal formulation

controls and releases the drug in a controlled manner compared to the faster release of drug by marketed

product. Consequently, transdermal patches of Trimetazidine hydrochloride showed promising results under

in- vitro conditions and thus there exist a scope for evaluation of the developed transdermal patches on suitable

models.